RxDoctor Payments Data

Joan Dean, MD

Neurology · Winston Salem, NCNPI 1902832850

Payments from drug & device makers

$3,376in general payments, 2019–2025

Across 125 payments — averaging $27.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • Livanova USA, Inc.$741
  • AbbVie$421
  • Aquestive Therapeutics, Inc.$273
  • Supernus Pharmaceuticals, Inc.$172
  • Greenwich Biosciences, Inc.$162
  • plus $243 from 6 others

What the payments were for

  • Speaking & faculty fees$3009%
  • Food & beverage$3,01689%
  • Education$612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,376 in reported general payments places this provider in the 60th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$11,144
Medicare patients
66
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)49$118,010
SympazanClobazam23$61,024
BriviactBrivaracetam37$56,513
XcopriCenobamate32$42,521
Trokendi XrTopiramate11$41,772
LamictalLamotrigine40$38,104
Depakote ErDivalproex Sodium46$36,364
TopamaxTopiramate22$35,884
KeppraLevetiracetam11$20,911
DepakoteDivalproex Sodium17$20,065
UbrelvyUbrogepant12$19,910
NayzilamMidazolam17$17,037
Lacosamide150$14,648
Oxtellar XrOxcarbazepine15$14,568
Carbamazepine ErCarbamazepine82$13,995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam$1,365$73,55054 claims
Aquestive Therapeutics, Inc.Sympazan$273$61,02423 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr, Oxtellar Xr$172$56,34026 claims
SK Life Science, Inc.Xcopri$107$42,52132 claims
AbbVieUbrelvy$421$19,91012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 566 neurology providers in North Carolina.

Other neurology in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →